NASDAQ:IOBT IO Biotech (IOBT) Stock Price, News & Analysis $0.05 0.00 (0.00%) As of 04/7/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About IO Biotech Stock (NASDAQ:IOBT) Get IO Biotech alerts:Sign Up Key Stats Today's Range$0.05▼$0.0550-Day Range$0.03▼$0.2252-Week Range$0.03▼$2.79VolumeN/AAverage Volume7.09 million shsMarket Capitalization$3.45 millionP/E RatioN/ADividend YieldN/APrice Target$3.50Consensus RatingReduce Company Overview IO Biotech ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, specializing in the development of novel immuno-oncology therapies. The company’s proprietary platform focuses on activating and sustaining anti-tumor immune responses by targeting the PD-L1 immune checkpoint. IO Biotech’s lead candidate, IO-VAC(R), is a peptide-based cancer vaccine designed to induce durable T-cell responses against PD-L1–expressing tumors. Since its founding in 2013, IO Biotech has advanced IO-VAC(R) into multiple clinical trials, including Phase II studies in patients with metastatic melanoma. The company’s pipeline also explores combination regimens that pair its vaccine technology with established checkpoint inhibitors to enhance therapeutic efficacy. Research and development activities are conducted in Denmark, with ongoing collaborations and trial sites across Europe and North America to support global patient access. IO Biotech is led by an experienced management team with deep expertise in immunology, oncology drug development and regulatory affairs. The company’s strategic focus remains on translating its innate immune-priming technology into differentiated cancer treatments and expanding its clinical footprint through partnerships and investigator-initiated studies.AI Generated. May Contain Errors. Read More Receive IOBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IO Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IOBT Stock News HeadlinesIO Biotech, Inc. (NASDAQ:IOBT) Receives Average Recommendation of "Reduce" from BrokeragesMay 13, 2026 | americanbankingnews.comIO Biotech: After Considering All Strategic Alternatives, Co. Ceased Operations and Filed aVoluntary Petition for Relief Under Provisions of Chapter 7 of Title 11 of U.S ...March 31, 2026 | marketwatch.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 23 at 1:00 AM | Paradigm Press (Ad)Why Are Shares Of IO Biotech Plummeting?March 31, 2026 | benzinga.comIO Biotech (IOBT) price target decreased by 33.83% to 1.66February 4, 2026 | msn.comIO Biotech Engages Raymond James as Financial Advisor Amid Workforce Reduction and Cost-Containment MeasuresJanuary 30, 2026 | quiverquant.comQIO Biotech Provides Corporate UpdateJanuary 30, 2026 | globenewswire.comPiper Sandler downgrades IO Biotech (IOBT)January 27, 2026 | msn.comSee More Headlines IOBT Stock Analysis - Frequently Asked Questions How have IOBT shares performed this year? IO Biotech's stock was trading at $0.6089 at the start of the year. Since then, IOBT shares have decreased by 92.1% and is now trading at $0.0480. How were IO Biotech's earnings last quarter? IO Biotech, Inc. (NASDAQ:IOBT) issued its quarterly earnings data on Friday, November, 14th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.03. When did IO Biotech IPO? IO Biotech (IOBT) raised $111 million in an initial public offering (IPO) on Thursday, November 4th 2021. The company issued 7,150,000 shares at a price of $14.00-$17.00 per share. How do I buy shares of IO Biotech? Shares of IOBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IO Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that IO Biotech investors own include Compass Pathways (CMPS), Nkarta (NKTX), PayPal (PYPL), AbCellera Biologics (ABCL), Atai Beckley (ATAI), Meta Platforms (META) and Company Calendar Last Earnings11/14/2025Today5/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 IOBT's financial health is in the Red zone, according to TradeSmith. IOBT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IOBT CIK1865494 Webwww.iobiotech.com Phone45-7070-2980FaxN/AEmployees30Year Founded2014Price Target and Rating Average Price Target for IO Biotech$3.50 High Price Target$4.00 Low Price Target$3.00 Potential Upside/Downside+7,191.7%Consensus RatingReduce Rating Score (0-4)1.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$95.49 million Net MarginsN/A Pretax MarginN/A Return on Equity-517.22% Return on Assets-200.69% Debt Debt-to-Equity Ratio18.29 Current Ratio2.01 Quick Ratio2.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book0.07Miscellaneous Outstanding Shares71,949,000Free Float68,495,000Market Cap$3.45 million OptionableNot Optionable Beta0.88 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:IOBT) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
